Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Medical Oncology
Do you hold or dose-modify FOLFOX for new hepatomegaly seen on a scan after starting treatment?
Does liver toxicity from FOLFOX resolve after discontinuation of the treatment?
Related Questions
In which situations do you omit the 5FU bolus in FOLFOX or FOLFIRI?
For a patient who has T4 squamous cell esophageal carcinoma on imaging, and who has biopsy-confirmed disease in an involved local lymph node, are EUS or EGD still indicated to complete workup?
How do you counsel patients and partners of patients with HPV+ cancers regarding the HPV vaccine?
Is there strong evidence to use TMB found in circulating tumor DNA to guide the use of ICI in metastatic colon cancer?
How would you approach patient with known Lynch Syndrome who developed a gall bladder cancer which on pathologic testing of the tumor by PCR and immunohistochemistry is pMMR and MSS?
How do you sequence HER2-therapy in HER2+ biliary tract cancer with the positive results of tucatinib + trastuzumab and zanidatamab in phase 2 studies?
How would you treat an MSI-H metastatic cholangiocarcinoma found on liquid biopsy?
What are your top takeaways from ESMO 2023?
How would you approach a gastric GIST with R1 resection?
How do you dose FOLFOX when given with concurrent chemoradiation in esophageal adenocarcinoma?